Evidence map›Paper›PMID 33867987›Full record

ArticleFrontiers in pharmacology2021

Quantitative Chemical Proteomics Reveals Resveratrol Inhibition of A549 Cell Migration Through Binding Multiple Targets to Regulate Cytoskeletal Remodeling and Suppress EMT.

Xiao Chen, Yutong Wang, Jing Tian, Yurou Shao, Bo Zhu, Jigang Wang, Zichun Hua

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Xiao ChenSchool of Medicine and Holistic Integrative Medicine and College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
Yutong WangSchool of Medicine and Holistic Integrative Medicine and College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
Jing TianSchool of Medicine and Holistic Integrative Medicine and College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
Yurou ShaoSchool of Medicine and Holistic Integrative Medicine and College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
Bo ZhuSchool of Medicine and Holistic Integrative Medicine and College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
Jigang WangArtemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Zichun HuaSchool of Medicine and Holistic Integrative Medicine and College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
China Pharmaceutical University · CNNanjing University of Chinese Medicine · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Resveratrol (RSV), a health-promoting natural product, has been shown to affect various cellular processes in tumor cells. However, the specific protein targets of RSV and the mechanism of action (MOA) of its anticancer effect remain elusive. In this study, the pharmacological activity of RSV was first evaluated in A549 cells, and the results showed that RSV significantly inhibited A549 cell migration but did not affect cell viability. To elucidate the underlying mechanism, a quantitative chemical proteomics approach was employed to identify the protein targets of RSV. A total of 38 target proteins were identified, and proteomic analysis showed that the targets were mainly involved in cytoskeletal remodeling and EMT, which were verified by subsequent

Indexed as

cytoskeletal remodelingEMTquantitative chemical proteomicsresveratroltarget identification

Identifiers

PMID33867987
PMCPMC8044895
OpenAlexW3143924582

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.